A

References

Barbujani, G., A. Magagni, E. Minch, and L. L. Cavalli-Sforza. 1997. An apportionment of human DNA diversity. Proceedings of the National Academy of Sciences 94(9):4516–4519. https://doi.org/10.1073/pnas.94.9.4516.

Benatar, M., J. Wuu, V. Lombardi, A. Jeromin, R. Bowser, P. M. Andersen, and A. Malaspina. 2019. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 20(7–8):538–548. https://doi.org/10.1080/21678421.2019.1646769.

Bryois, J., N. G. Skene, T. F. Hansen, L. J. Kogelman, H. J. Watson, Z. Liu, Easting Disorders Working Group of the Psychiatric Genomics Consortium, International Headache Genetics Consortium, 23andMe Research Team, L. Brueggeman, G. Breen, C. M. Bulik, E. Arenas, J. Hjerling-Leffler, and P. F Sullivan. 2020. Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson’s disease. Nature Genetics 52(5):482–493. https://doi.org/10.1038/s41588-020-0610-9.

Burbulla, L. F., P. Song, J. R. Mazzulli, E. Zampese, Y. C. Wong, S. Jeon, D. P. Santos, J. Blanz, C. D. Obermaier, C. Strojny, J. N. Savas, E. Kiskinis, X. Zhuang, R. Kruger, D. J. Surmeier, and D. Krainc. 2017. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease. Science 357(6357):1255–1261. https://doi.org/10.1126/science.aam9080.

de Leeuw, C. A., J. M. Mooij, T. Heskes, and D. Posthuma. 2015. MAGMA: Generalized gene-set analysis of GWAS data. PLoS Computational Biology 11(4):e1004219. https://doi.org/10.1371/journal.pcbi.1004219.

De Schaepdryver, M., C. Lunetta, C. Tarlarini, L. Mosca, A. Chio, P. Van Damme, and K. Poesen. 2020. Neurofilament light chain and C reactive protein explored as predictors of survival in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 91(4):436–437. https://doi.org/10.1136/jnnp-2019-322309.

Doàn, L. N., Y. Takata, K. L. K. Sakuma, and V. L. Irvin. 2019. Trends in clinical research including Asian American, Native Hawaiian, and Pacific Islander participants funded by the US National Institutes of Health, 1992 to 2018. JAMA Network Open 2(7):e197432. https://doi.org/10.1001/jamanetworkopen.2019.7432.

Dräger, N.M., S. M. Sattler, C. T. L. Huang, O. M. Teter, K. Leng, S. H. Hashemi, J. Hong, C. D. Clelland, L. Zhan, L. Kodama, A. B. Singleton, M. A. Nalls, J. Ichida, M. E. Ward, F. Faghri, L. Gan, and M. Kampmann. 2021. A CRISPRi/a platform in iPSC-derived microglia uncovers regulators of disease states. bioRxiv. https://doi.org/10.1101/2021.06.16.448639.

Fayer, S., C. Horton, J. N. Dines, A. F. Rubin, M. E. Richardson, K. McGoldrick, F. Hernandez, T. Pesaran, R. Karam, B. H. Shirts, D. M. Fowler, and L. M. Starita. 2021. Closing the gap: Systematic integration of multiplexed functional data resolves variants of uncertain significance in BRCA1, TP53, and PTEN. The American Journal of Human Genetics 108(12):2248–2258. https://doi.org/10.1016/j.ajhg.2021.11.001.

Findlay, G. M., R. M. Daza, B. Martin, M. D. Zhang, A. P. Leith, M. Gasperini, J. D. Janizek, X. Huang, L. M. Starita, and J. Shendure. 2018. Accurate classification of BRCA1 variants with saturation genome editing. Nature 562(7726):217–222. https://doi.org/10.1038/s41586-018-0461-z.

FDA (Food and Drug Administration). 2016. FDA approves first drug for spinal muscular atrophy. FDA News Release, December 23. https://www.fda.gov/news-events/pressannouncements/fda-approves-first-drug-spinal-muscular-atrophy (accessed February 1, 2022).

FDA. 2020a. FDA approves new therapy for Dravet syndrome. FDA News Release, June 25. https://www.fda.gov/news-events/press-announcements/fda-approves-new-therapy-dravet-syndrome (accessed February 1, 2022).

FDA. 2020b. FDA approves oral treatment for spinal muscular atrophy. FDA News Release, August 7. https://www.fda.gov/news-events/press-announcements/fda-approves-oral-treatment-spinal-muscular-atrophy (accessed February 1, 2022).

García-Gutiérrez, M. S., F. Navarrete, F. Sala, A. Gasparyan, A. Austrich-Olivares, and J. Manzanares. 2020. Biomarkers in psychiatry: Concept, definition, types and relevance to the clinical reality. Frontiers in Psychiatry 11:432. https://doi.org/10.3389/fpsyt.2020.00432.

Geschwind, D. H., and G. Konopka. 2009. Neuroscience in the era of functional genomics and systems biology. Nature 461(7266):908–915. https://doi.org/10.1038/nature08537.

Gilbert, L. A., M. A. Horlbeck, B. Adamson, J. E. Villalta, Y. Chen, E. H. Whitehead, C. Guimaraes, B. Panning, H. L. Ploegh, M. C. Bassik, L. S. Qi, M. Kampmann, and J. S. Weissman. 2014. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159(3):647–661. https://doi.org/10.1016/j.cell.2014.09.029.

Hindorff, L. A., V. L. Bonham, L. C. Brody, M. E. C. Ginoza, C. M. Hutter, T. A. Manolio, and E. D. Green. 2018. Prioritizing diversity in human genomics research. Nature Reviews Genetics 19(3):175–185. https://doi.org/10.1038/nrg.2017.89.

Huber, G., G. Gross, R. Schüttler, and M. Linz. 1980. Longitudinal studies of schizophrenic patients. Schizophrenia Bulletin 6(4):592–605. https://doi.org/10.1093/schbul/6.4.592.

Inouye, M., G. Abraham, C. P. Nelson, A. M. Wood, M. J. Sweeting, F. Dudbridge, F. Y. Lai, S. Kaptoge, M. Brozynska, T. Wang, S. Ye, T. R. Webb, M. K. Rutter, I. Tzoulaki, R. S. Patel, R. J. F. Loos, B. Keavney, H. Hemingway, J. Thompson, H. Watkins, P. Deloukas, E. D. Angelantonio, A. S. Butterworth, J. Danesh, and N. J. Samani. 2018. Genomic risk prediction of coronary artery disease in 480,000 adults: Implications for primary prevention. Journal of the American College of Cardiology 72(16):1883–1893. https://doi.org/10.1016/j.jacc.2018.07.079.

IOM (Institute of Medicine). 2013. Improving the utility and translation of animal models for nervous system disorders: Workshop summary. Washington, DC: The National Academies Press.

IOM. 2014. Improving and accelerating therapeutic development for nervous system disorders: Workshop summary. Washington, DC: The National Academies Press.

Jack, C. R., D. S. Knopman, W. J. Jagust, L. M. Shaw, P. S. Aisen, M. W. Weiner, R. C. Petersen, and J. Q. Trojanowski. 2010. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. The Lancet Neurology 9(1):119. https://doi.org/10.1016/S1474-4422(09)70299-6.

Jack, C. R., D. S. Knopman, W. J. Jagust, R. C. Petersen, M. W. Weiner, P. S. Aisen, L. M. Shaw, P. Vemuri, H. J. Wise, S. D. Weigand, T. G. Lesnick, V. S. Pankratz, M. C. Donohue, and J. Q. Trojanowski. 2013. Tracking pathophysiological processes in Alzheimer’s disease: An updated hypothetical model of dynamic biomarkers. The Lancet Neurology 12(2):207–216. https://doi.org/10.1016/S1474-4422(12)70291-0.

Jack, C. R., D. A. Bennett, K. Blennow, M. C. Carrillo, B. Dunn, S. B. Haeberlein, D. M. Holtzman, W. Jagust, F. Jessen, J. Karlawish, E. Liu, J. L. Molinuevo, T. Montine, C. Phelps, K. P. Rankin, C. C. Rowe, P. Scheltens, E. Siemers, H. M. Snyder, R. Sperling, C. Elliot, E. Masliah, L. Ryan, and N. Silverberg. 2018. NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 14(4):535–562. https://doi.org/10.1016/j.jalz.2018.02.018.

Jarvis, L. M. 2012. Tough times for neuroscience R&D. Chemical & Engineering News https://cen.cs.org/articles/90/i12/Tough-Times-Neuroscience-RD.html (accessed November 4, 2021).

Jaworski, K., P. Jankowski, and D. A. Kosior. 2017. PCSK9 inhibitors – From discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade. Archives of Medical Science: AMS 13(4):914–929. https://doi.org/10.5114/aoms.2017.65239.

Jorde, L. B., W. S. Watkins, M. J. Bamshad, M. E. Dixon, C. E. Ricker, M. T. Seielstad, and M. A. Batzer. 2000. The distribution of human genetic diversity: a comparison of mitochondrial, autosomal, and Y-chromosome data. The American Journal of Human Genetics 66(3):979–988. https://doi.org/10.1086/302825.

Kampmann, M. 2020. CRISPR-based functional genomics for neurological disease. Nature Reviews Neurology 16(9):465–480. https://doi.org/10.1038/s41582-020-0373-z.

Krienen, F. M., M. Goldman, Q. Zhang, R. C. Del Rosario, M. Florio, R. Machold, A. Saunders, K. Levandowski, H. Zaniewski, B. Schuman, and C. Wu. 2020. Innovations present in the primate interneuron repertoire. Nature 586(7828):262–269. https://doi.org/10.1038/s41586-020-2781-z.

Kuksa, P. P., C.-L. Liu, W. Fu, L. Qu, Y. Zhao, Z. Katanic, K. Clark, A. Kuzma, P.-C. Ho, K.-T. Tzeng, O. Valladares, S.-Y. Chou, A. C. Naj, G. D. Schellenberg, L.-S. Wang, Y. Y. Leung. 2020. Alzheimer’s disease variant portal (ADVP): A catalog of genetic findings for Alzheimer’s disease. MedRxiv. https://doi.org/10.1101/2020.09.29.20203950.

Lewontin R. C. 1972. The apportionment of human diversity. In: Dobzhansky T., M. K. Hecht, W. C. Steere (eds) Evolutionary Biology. Springer, New York, NY. https://doi.org/10.1007/978-1-4684-9063-3_14.

Martin, A. R., M. Kanai, Y. Kamatani, Y. Okada, B. M. Neale, and M. J. Daly. 2019. Clinical use of current polygenic risk scores may exacerbate health disparities. Nature Genetics 51(4):584–591. https://doi.org/10.1038/s41588-019-0379-x.

Maserejian, N., L. Vinikoor-Imler, and A. Dilley. 2020. Estimation of the 2020 global population of Parkinson’s disease (PD) [Abstract]. Movement Disorders: Official Journal of the Movement Disorder Society 35(Suppl 1). https://www.mdsabstracts.org/abstract/estimation-of-the-2020-global-population-of-parkinsons-disease-pd (accessed November 4, 2021).

Morgan, P., D. G. Brown, S. Lennard, M. J. Anderton, J. C. Barrett, U. Eriksson, M. Fidock, B. Hamren, A. Johnson, R. E. March, J. Matcham, J. Mettetal, D. J. Nicholls, S. Platz, S. Rees, M. A. Snowden, and M. N. Pangalos. 2018. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nature Reviews Drug Discovery 17(3):167–181. https://doi.org/10.1038/nrd.2017.244.

NASEM (National Academies of Sciences, Engineering, and Medicine). 2017. Therapeutic development in the absence of predictive animal models of nervous system disorders: Proceedings of a workshop. Washington, DC: The National Academies Press.

Paulsen, B., S. Velasco, A. J. Kedaigle, M. Pigoni, G. Quadrato, A. Deo, X. Adiconis, A. Uzquiano, K. Kim, S. K. Simmons, K. Tsafou, A. Albanese, R. Sartore, C. Abbate, A. Tucewicz, S. Smith, K. Chung, K. Lage, A. Regev, J. Z. Levin, and P. Arlotta. 2020. Human brain organoids reveal accelerated development of cortical neuron classes as a shared feature of autism risk genes. bioRxiv. https://doi.org/10.1101/2020.11.10.376509.

Quadrato, G., T. Nguyen, E. Z. Macosko, J. L. Sherwood, S. M. Yang, D. R. Berger, N. Maria, J. Scholvin, M. Goldman, J. P. Kinney, E. S. Boyden, J. W. Lichtman, Z. M. Williams, S. A. McCarroll, and P. Arlotta. 2017. Cell diversity and network dynamics in photosensitive human brain organoids. Nature 545(7652):48–53. https://doi.org/10.1038/nature22047.

Sekar, A., A. R. Bialas, H. de Rivera, A. Davis, T. R. Hammond, N. Kamitaki, K. Tooley, J. Preumey, M. Baum, V. Van Doren, G. Genovese, S. A. Rose, R. E. Handsaker, Schizophrenia Working Group of the Psychiatric Genomics Consortium, M. J. Daly, M. C. Carroll, B. Stevens, and S. A. McCarroll. 2016. Schizophrenia risk from complex variation of complement component 4. Nature 530(7589):177–183. https://doi.org/10.1038/nature16549.

Shi, Y., S. Lin, K. A. Staats, Y. Li, W. Chang, S. Hung, E. Hendricks et al. 2018. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nature Medicine 24(3):313–325. https://doi.org/10.1038/nm.4490.

Sirugo, G., S. M. Williams, and S. A. Tishkoff. 2019. The missing diversity in human genetic studies. Cell 177(1):26–31. https://doi.org/10.1016/j.cell.2019.02.048.

Skene, N. G., J. Bryois, T. E. Bakken, G. Breen, J. J. Crowley, H. A. Gaspar, P. GiustiRodriguez, R. D. Hodge, J. A. Miller, A. B. Munoz-Manchado, M. C. O’Donovan, M. J. Owen, A. F. Pardinas, J. Ryge, J. T. R. Walters, S. Linnarsson, E. S. Lein, P. F. Sullivan, and J. Hjerling-Leffler. 2018. Genetic identification of brain cell types underlying schizophrenia. Nature Genetics 50(6):825–833. https://doi.org/10.1038/s41588-018-0129-5.

Thomas, D. W. 2016. Clinical development success rates 2006–2015. BIO, Biomedtracker, Amplion https://www.bio.org/sites/default/files/legacy/bioorg/docs/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf (accessed November 4, 2021).

Tijms, B. M., J. Gobom, L. Reus, I. Jansen, S. Hong, V. Dobricic, F. Kilpert et al. 2020. Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics. Brain: A Journal of Neurology 143(12):3776–3792. https://doi.org/10.1093/brain/awaa325.

Tishkoff, S. A., F. A. Reed, F. R. Friedlaender, C. Ehret, A. Ranciaro, A. Froment, J. B. Hirbo, A. A. Awomoyi, J. Bodo, O. Doumbo, M. Ibrahim, A. T. Juma, M. J. Kotze, G. Lema, J. H. Moore, H. Mortensen, T. B. Nyambo, S. A. Omar, K. Powell, G. S. Pretorius, M. W. Smith, M. A. Thera, C. Wambebe, J. L. Weber, and S. M. Williams. 2009. The genetic structure and history of Africans and African Americans. Science 324(5930):1035–1044. https://doi.org/10.1126/science.1172257.

Velasco, S., A. J. Kedaigle, S. K. Simmons, A. Nash, M. Rocha, G. Quadrato, B. Paulsen, L. Nguyen, X. Adiconis, A. Regev, J. Z. Levin, and P. Arlotta. 2019. Individual brain organoids reproducibly form cell diversity of the human cerebral cortex. Nature 570(7762):523–527. https://doi.org/10.1038/s41586-019-1289-x.

Watanabe, K., E. Taskesen, A. van Bochoven, and D. Posthuma. 2017. Functional mapping and annotation of genetic associations with FUMA. Nature Communications 8(1):1826. https://doi.org/10.1038/s41467-017-01261-5.

Werme, J., S. van der Sluis, D. Posthuma, and C. de Leeuw. 2021. LAVA: An integrated framework for local genetic correlation analysis. BiorXiv preprint. doi: 10.1101/2020.12.31.424652.

Weydt, P., P. Oeckl, A. Huss, K. Müller, A. E. Volk, J. Kuhle, A. Knehr, P. M. Anderson, J. Prudlo, P. Steinacker, J. H. Weishaupt, A. C. Ludolph, and M. Otto. 2016. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Annals of Neurology 79(1):152–158. https://doi.org/10.1002/ana.24552.

This page intentionally left blank.